Nuala Brennan
Directeur Technique/Scientifique/R&D chez MOONLAKE IMMUNOTHERAPEUTICS
Profil
Nuala Brennan is currently the Chief Clinical Development Officer at MoonLake Immunotherapeutics and Moonlake Immunotherapeutics Ltd.
Prior to her current position, she worked as the Vice President-Clinical Operations at Kymab Ltd.
Ms. Brennan completed her undergraduate degree at the University of Leicester.
Postes actifs de Nuala Brennan
| Sociétés | Poste | Début |
|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | Directeur Technique/Scientifique/R&D | 01/09/2021 |
| Moonlake Immunotherapeutics Ltd. | Directeur Technique/Scientifique/R&D | 01/09/2021 |
Anciens postes connus de Nuala Brennan
| Sociétés | Poste | Fin |
|---|---|---|
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Directeur Technique/Scientifique/R&D | 01/08/2021 |
Formation de Nuala Brennan
| University of Leicester | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Moonlake Immunotherapeutics Ltd. | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
